What happened on debut
Bambusa sold shares at $16 in its U.S. IPO, pulling in $168.9 million. The stock then finished its first session at $14.99, a 6.3% slide from the offer price.
At that closing level, the company was valued near $763.6 million, based on the shares outstanding listed in regulatory documents. Trading is on the Nasdaq Global Select Market, where it trades as BBTX.
Company background and pipeline
Launched in 2024 and headquartered in Boston, Bambusa is building long-acting bispecific antibodies aimed at the broad immunology and inflammation category, spanning skin, respiratory, gastroenterology and autoimmune conditions.
Its lead programs came through acquiring assets from one of BioNTech SE's units. One is designed for atopic dermatitis, and another targets additional inflammatory diseases, including respiratory and allergic disorders. "This is really a pivotal point for the company," said Chief Executive Officer Shanshan Xu. "A clinical validation for the lead program is really a breakthrough across the entire pipeline because the entire pipeline shares the same underlying technology."
Market twists remind active investors that smarter tools can help maintain a thoughtful edge. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Financing, ownership and finances
Bookrunners were Bank of America Corp., Evercore Inc., UBS Group AG and Cantor Fitzgerald. After the offering, Salvia Investment was expected to hold nearly 18%, Xu about 17%, and RA Capital Management roughly 9%.
Bambusa closed a financing in November that brought in $33.1 million from existing backers including RA Capital, Janus Henderson Investors and KKR & Co.-controlled Dawn Biopharma. That round came at a meaningfully higher valuation than an $89 million raise earlier in the year. As of June 30, Bambusa reported $71.5 million in cash and cash equivalents. For the first half ending June 30, it posted a net loss of $22.4 million with no revenue, compared with a $13.0 million loss and no revenue in the same stretch a year earlier.
What this means for your portfolio
Early-stage biotech IPOs tend to trade on milestones more than revenue, and Bambusa is squarely in that camp: fresh cash from the listing, ongoing losses, and a pipeline built around the same antibody platform. Add the float, the lead programs' focus areas, and the new cap table, and you have the markers to watch for price-moving updates.
Learning how AI can inform your decisions may quietly improve long term investing outcomes. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
